{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:27:10Z","timestamp":1785331630786,"version":"3.55.0"},"reference-count":102,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,3]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The development of targeted therapy for patients with multiple myeloma (MM) is hampered by the low frequency of actionable genetic abnormalities. Gain or amplification of chromosome 1q (1q+) is the most frequent arm-level copy number gain in patients with MM and is associated with higher risk of progression and death despite recent therapeutic advances. Thus, developing targeted therapy for patients with MM with 1q+ stands to benefit a large portion of patients in need of more effective management. Here, we used large-scale dependency screens and drug screens to systematically characterize the therapeutic vulnerabilities of MM with 1q+ and displayed increased sensitivity to myeloid cell leukemia-1 (MCL1) and phosphatidyl inositol 3-kinase (PI3K) inhibitors. Using single-cell RNA sequencing, we compared subclones with and without 1q+ within the same patient tumors and demonstrated that 1q+ is associated with higher levels of MCL1 and the PI3K pathway. Furthermore, by isolating isogenic clones with different copy number profiles for part of the chromosome 1q arm, we observed increased sensitivity to MCL1 and PI3K inhibitors with arm-level gain. Lastly, we demonstrated synergy between MCL1 and PI3K inhibitors and dissected their mechanism of action in MM with 1q+, uncovering a cytostatic effect. In conclusion, this study highlights that MM with 1q+ may present enhanced sensitivity to MCL1 and PI3K inhibitors, enabling their use at lower doses without sacrificing efficacy, and may thus accelerate the development of targeted therapy for patients with MM and 1q+.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024025102","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T20:22:26Z","timestamp":1741810946000},"page":"89-103","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+"],"prefix":"10.1182","volume":"146","author":[{"given":"Romanos","family":"Sklavenitis-Pistofidis","sequence":"first","affiliation":[{"name":"1Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"},{"name":"4Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Lightbody","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairead","family":"Reidy","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-3750","authenticated-orcid":false,"given":"Junko","family":"Tsuji","sequence":"additional","affiliation":[{"name":"3Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-7294","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Alberge","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8230-5726","authenticated-orcid":false,"given":"Michelle P.","family":"Aranha","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4296-015X","authenticated-orcid":false,"given":"Daniel","family":"Heilpern-Mallory","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey G.","family":"Roweth","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Huynh","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J. F.","family":"Chong","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"5Department of Physiology, National University of Singapore Centre for Cancer Research, National University of Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Y.","family":"Chung","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3330-2369","authenticated-orcid":false,"given":"Liam","family":"Hackett","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-3135","authenticated-orcid":false,"given":"Nicholas J.","family":"Haradhvala","sequence":"additional","affiliation":[{"name":"3Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4081-0660","authenticated-orcid":false,"given":"Ting","family":"Wu","sequence":"additional","affiliation":[{"name":"3Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2875-6590","authenticated-orcid":false,"given":"Nang K.","family":"Su","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Berrios","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1542-8996","authenticated-orcid":false,"given":"Saveliy","family":"Belkin","sequence":"additional","affiliation":[{"name":"3Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2535-3729","authenticated-orcid":false,"given":"Ankit K.","family":"Dutta","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Knudson","sequence":"additional","affiliation":[{"name":"6Mayo Clinic, Office of Core Shared Services, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Brandt","sequence":"additional","affiliation":[{"name":"6Mayo Clinic, Office of Core Shared Services, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5536-9011","authenticated-orcid":false,"given":"Patricia T.","family":"Greipp","sequence":"additional","affiliation":[{"name":"6Mayo Clinic, Office of Core Shared Services, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Papaioannou","sequence":"additional","affiliation":[{"name":"4Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"},{"name":"7Hematology Unit, First Internal Medicine Department, AHEPA University Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Getz","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"3Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"},{"name":"8Department of Pathology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-711X","authenticated-orcid":false,"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[{"name":"9Cancer Heterogeneity, Plasticity and Resistance to Therapies Unit, INSERM UMRS1277, Centre National de la Recherche Scientifique UMR9020, Lille University, Lille, France"},{"name":"10Department of Hematology, Centre Hospitalier Universitaire Lille, Lille University, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2025070311221707400_bib1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood.2022017010","article-title":"Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed\/refractory myeloma","volume":"141","author":"Ansari-Pour","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025070311221707400_bib2","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun"},{"key":"2025070311221707400_bib3","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"21","key":"2025070311221707400_bib4","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7339","key":"2025070311221707400_bib5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"8","key":"2025070311221707400_bib6","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3324\/haematol.2021.279360","article-title":"Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities","volume":"107","author":"Giesen","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"2025070311221707400_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"2025070311221707400_bib8","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"2025070311221707400_bib9","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"issue":"33","key":"2025070311221707400_bib10","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025070311221707400_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"2025070311221707400_bib12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2025070311221707400_bib13","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2025070311221707400_bib14","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/sj.leu.2403090","article-title":"Many and multiple myeloma(s)","volume":"17","author":"Fonseca","year":"2003","journal-title":"Leukemia"},{"issue":"11","key":"2025070311221707400_bib15","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2025070311221707400_bib16","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"7","key":"2025070311221707400_bib17","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","article-title":"The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma","volume":"102","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2025070311221707400_bib18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2025070311221707400_bib19","first-page":"2950","article-title":"Multiple myeloma with t(11;14): unique biology and evolving landscape","volume":"12","author":"Bal","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"4","key":"2025070311221707400_bib20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ajh.26083","article-title":"Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma","volume":"96","author":"Kaufman","year":"2021","journal-title":"Am J Hematol"},{"issue":"12","key":"2025070311221707400_bib21","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"2025070311221707400_bib22","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/j.cell.2023.03.029","article-title":"KaryoCreate: a CRISPR-based technology to study chromosome-specific aneuploidy by targeting human centromeres","volume":"186","author":"Bosco","year":"2023","journal-title":"Cell"},{"key":"2025070311221707400_bib23","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1038\/ncomms4728","article-title":"Targeted genomic rearrangements using CRISPR\/Cas technology","volume":"5","author":"Choi","year":"2014","journal-title":"Nat Commun"},{"issue":"21","key":"2025070311221707400_bib24","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1093\/nar\/gkab557","article-title":"Engineering large-scale chromosomal deletions by CRISPR-Cas9","volume":"49","author":"Eleveld","year":"2021","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2025070311221707400_bib25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13059-017-1354-4","article-title":"CRISPR\/Cas9-mediated targeted chromosome elimination","volume":"18","author":"Zuo","year":"2017","journal-title":"Genome Biol"},{"issue":"15","key":"2025070311221707400_bib26","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","article-title":"Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities","volume":"4","author":"Abdallah","year":"2020","journal-title":"Blood Adv"},{"issue":"16","key":"2025070311221707400_bib27","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2011.36.5726","article-title":"Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival","volume":"30","author":"Avet-Loiseau","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025070311221707400_bib28","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/s41375-020-01096-y","article-title":"Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial","volume":"35","author":"Croft","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"2025070311221707400_bib29","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2019001425","article-title":"Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents","volume":"4","author":"Giri","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2025070311221707400_bib30","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2004-04-1319","article-title":"Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma","volume":"104","author":"Guti\u00e9rrez","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2025070311221707400_bib31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/cancers13020256","article-title":"Gain\/amplification of chromosome arm 1q21 in multiple myeloma","volume":"13","author":"Hanamura","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2025070311221707400_bib32","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2025070311221707400_bib33","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/ajh.25994","article-title":"The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event","volume":"95","author":"Locher","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"2025070311221707400_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.16292","article-title":"Daratumumab in high-risk relapsed\/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain\/amplification and GEP70 status on outcome","volume":"189","author":"Mohan","year":"2020","journal-title":"Br J Haematol"},{"issue":"12","key":"2025070311221707400_bib35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"issue":"4","key":"2025070311221707400_bib36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025070311221707400_bib37","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1080\/10428194.2016.1260126","article-title":"Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation","volume":"58","author":"Shah","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025070311221707400_bib38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"2025070311221707400_bib39","doi-asserted-by":"crossref","first-page":"961421","DOI":"10.3389\/fonc.2022.961421","article-title":"Multiple myeloma with amplification of Chr1q: therapeutic opportunity and challenges","volume":"12","author":"Sklavenitis-Pistofidis","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"2025070311221707400_bib40","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.3324\/haematol.2021.278888","article-title":"Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients","volume":"106","author":"Weinhold","year":"2021","journal-title":"Haematologica"},{"issue":"10","key":"2025070311221707400_bib41","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"4","key":"2025070311221707400_bib42","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41375-019-0634-2","article-title":"Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma","volume":"34","author":"Merz","year":"2020","journal-title":"Leukemia"},{"issue":"34","key":"2025070311221707400_bib43","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025070311221707400_bib44","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"9","key":"2025070311221707400_bib45","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-14-2576","article-title":"The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma","volume":"21","author":"An","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2025070311221707400_bib46","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-22-3209","article-title":"Multiomic mapping of acquired chromosome 1 copy-number and structural variants to identify therapeutic vulnerabilities in multiple myeloma","volume":"29","author":"Boyle","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025070311221707400_bib47","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","article-title":"High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients","volume":"9","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"issue":"14","key":"2025070311221707400_bib48","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","article-title":"Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma","volume":"129","author":"Gupta","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2025070311221707400_bib49","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1158\/1078-0432.CCR-15-0254","article-title":"NEDD8 inhibition overcomes CKS1B-induced drug resistance by upregulation of p21 in multiple myeloma","volume":"21","author":"Huang","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025070311221707400_bib50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ccell.2017.05.011","article-title":"ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma","volume":"32","author":"Marchesini","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"2025070311221707400_bib51","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ni.2527","article-title":"Mcl-1 is essential for the survival of plasma cells","volume":"14","author":"Peperzak","year":"2013","journal-title":"Nat Immunol"},{"issue":"1","key":"2025070311221707400_bib52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18632\/oncotarget.105","article-title":"Over-expression of CKS1B activates both MEK\/ERK and JAK\/STAT3 signaling pathways and promotes myeloma cell drug-resistance","volume":"1","author":"Shi","year":"2010","journal-title":"Oncotarget"},{"issue":"24","key":"2025070311221707400_bib53","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","article-title":"Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting","volume":"3","author":"Slomp","year":"2019","journal-title":"Blood Adv"},{"issue":"148","key":"2025070311221707400_bib54","doi-asserted-by":"crossref","first-page":"148ra117","DOI":"10.1126\/scitranslmed.3003808","article-title":"Targeted disruption of the BCL9\/\u03b2-catenin complex inhibits oncogenic Wnt signaling","volume":"4","author":"Takada","year":"2012","journal-title":"Sci Transl Med"},{"issue":"13","key":"2025070311221707400_bib55","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1182\/blood.2021014391","article-title":"Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma","volume":"139","author":"Trasanidis","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025070311221707400_bib56","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"issue":"3","key":"2025070311221707400_bib57","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"issue":"1","key":"2025070311221707400_bib58","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s13059-021-02540-7","article-title":"Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects","volume":"22","author":"Dempster","year":"2021","journal-title":"Genome Biol"},{"issue":"1","key":"2025070311221707400_bib59","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1038\/s41467-018-06916-5","article-title":"Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration","volume":"9","author":"McFarland","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"2025070311221707400_bib60","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"issue":"12","key":"2025070311221707400_bib61","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers","year":"2017","journal-title":"Nat Genet"},{"issue":"12","key":"2025070311221707400_bib62","doi-asserted-by":"crossref","first-page":"e51942","DOI":"10.1371\/journal.pone.0051942","article-title":"C911: a bench-level control for sequence specific siRNA off-target effects","volume":"7","author":"Buehler","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"2025070311221707400_bib63","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.leu.2404253","article-title":"Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations","volume":"20","author":"Hanamura","year":"2006","journal-title":"Leukemia"},{"issue":"10","key":"2025070311221707400_bib64","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"Cancer Genome Atlas Research Network. The cancer genome atlas pan-cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"2025070311221707400_bib65","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"issue":"4","key":"2025070311221707400_bib66","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The Drug Repurposing Hub: a next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat Med"},{"issue":"18","key":"2025070311221707400_bib67","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"issue":"3","key":"2025070311221707400_bib68","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41587-022-01468-y","article-title":"Haplotype-aware analysis of somatic copy number variations from single-cell transcriptomes","volume":"41","author":"Gao","year":"2023","journal-title":"Nat Biotechnol"},{"key":"2025070311221707400_bib100","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41467-024-55308-5","article-title":"Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial","volume":"16","author":"Nadeem","year":"2025","journal-title":"Nat Commun"},{"key":"2025070311221707400_bib101","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41467-025-56323-w","article-title":"Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia","volume":"16","author":"Sklavenitis-Pistofidis","year":"2025","journal-title":"Nat Commun"},{"key":"2025070311221707400_bib102","doi-asserted-by":"publisher","DOI":"10.1101\/2024.04.19.24306082","article-title":"Long-term follow-up defines the population that benefits from early interception in a high-risk smoldering multiple myeloma clinical trial using the combination of ixazomib, lenalidomide, and dexamethasone","author":"Nadeem","year":"19  2024","journal-title":"medRxiv"},{"key":"2025070311221707400_bib69","doi-asserted-by":"crossref","first-page":"14049","DOI":"10.1038\/ncomms14049","article-title":"Massively parallel digital transcriptional profiling of single cells","volume":"8","author":"Zheng","year":"2017","journal-title":"Nat Commun"},{"issue":"9","key":"2025070311221707400_bib70","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"issue":"28","key":"2025070311221707400_bib71","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1038\/onc.2014.307","article-title":"UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation","volume":"34","author":"Itkonen","year":"2015","journal-title":"Oncogene"},{"issue":"1","key":"2025070311221707400_bib72","doi-asserted-by":"crossref","first-page":"8685","DOI":"10.1038\/s41467-024-52725-4","article-title":"An automated network-based tool to search for metabolic vulnerabilities in cancer","volume":"15","author":"Valc\u00e1rcel","year":"2024","journal-title":"Nat Commun"},{"key":"2025070311221707400_bib73","doi-asserted-by":"crossref","first-page":"100672","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev"},{"issue":"8","key":"2025070311221707400_bib74","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","article-title":"The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities","volume":"5","author":"Ramberger","year":"2024","journal-title":"Nat Cancer"},{"issue":"35","key":"2025070311221707400_bib75","doi-asserted-by":"crossref","first-page":"E3689","DOI":"10.1073\/pnas.1405801111","article-title":"The role of PI3K\/AKT-related PIP5K1\u03b1 and the discovery of its selective inhibitor for treatment of advanced prostate cancer","volume":"111","author":"Semenas","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"2025070311221707400_bib76","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-18-0549","article-title":"Tyrosine kinase inhibitors increase MCL1 degradation and in combination with BCLXL\/BCL2 inhibitors drive prostate cancer apoptosis","volume":"24","author":"Arai","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2025070311221707400_bib77","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1158\/0008-5472.CAN-19-0950","article-title":"Mcl-1 interacts with Akt to promote lung cancer progression","volume":"79","author":"Chen","year":"2019","journal-title":"Cancer Res"},{"issue":"1","key":"2025070311221707400_bib78","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"issue":"15","key":"2025070311221707400_bib79","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1158\/0008-5472.CAN-10-4531","article-title":"Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition","volume":"71","author":"Coloff","year":"2011","journal-title":"Cancer Res"},{"issue":"46","key":"2025070311221707400_bib80","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1038\/s41388-022-02482-9","article-title":"AKT-mTORC1 reactivation is the dominant resistance driver for PI3K\u03b2\/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors","volume":"41","author":"Dunn","year":"2022","journal-title":"Oncogene"},{"issue":"1","key":"2025070311221707400_bib81","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1038\/s41467-022-33944-z","article-title":"Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis","volume":"13","author":"Boiarsky","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"2025070311221707400_bib82","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","article-title":"A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance","volume":"123","author":"Tian","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2025070311221707400_bib83","doi-asserted-by":"crossref","first-page":"bbab413","DOI":"10.1093\/bib\/bbab413","article-title":"sciCNV: high-throughput paired profiling of transcriptomes and DNA copy number variations at single-cell resolution","volume":"23","author":"Mahdipour-Shirayeh","year":"2022","journal-title":"Brief Bioinform"},{"issue":"50","key":"2025070311221707400_bib84","doi-asserted-by":"crossref","first-page":"39458","DOI":"10.1074\/jbc.M006626200","article-title":"Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen","volume":"275","author":"Fujise","year":"2000","journal-title":"J Biol Chem"},{"key":"2025070311221707400_bib85","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.1038\/ncomms7891","article-title":"The NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrest","volume":"6","author":"Haschka","year":"2015","journal-title":"Nat Commun"},{"issue":"5","key":"2025070311221707400_bib86","doi-asserted-by":"crossref","first-page":"5176","DOI":"10.18632\/oncotarget.6894","article-title":"Mcl-1 dynamics influence mitotic slippage and death in mitosis","volume":"7","author":"Sloss","year":"2016","journal-title":"Oncotarget"},{"issue":"7336","key":"2025070311221707400_bib87","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature09779","article-title":"Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7","volume":"471","author":"Wertz","year":"2011","journal-title":"Nature"},{"issue":"4","key":"2025070311221707400_bib88","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/cells8040346","article-title":"Regulating the BCL2 family to improve sensitivity to microtubule targeting agents","volume":"8","author":"Whitaker","year":"2019","journal-title":"Cells"},{"issue":"1","key":"2025070311221707400_bib89","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s42003-021-02564-6","article-title":"The multiple mechanisms of MCL1 in the regulation of cell fate","volume":"4","author":"Widden","year":"2021","journal-title":"Commun Biol"},{"key":"2025070311221707400_bib90","doi-asserted-by":"crossref","first-page":"543066","DOI":"10.3389\/fcell.2020.543066","article-title":"Upregulation of Mcl-1S causes cell-cycle perturbations and DNA damage accumulation","volume":"8","author":"Streletskaia","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2025070311221707400_bib91","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbrc.2008.12.015","article-title":"Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0\/G1 arrest","volume":"379","author":"Dan","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"2025070311221707400_bib92","first-page":"445","article-title":"Effect of PI3K\/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells","volume":"32","author":"Fekete","year":"2012","journal-title":"Anticancer Res"},{"issue":"3","key":"2025070311221707400_bib93","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-06-0639","article-title":"Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated","volume":"6","author":"Fujiwara","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2025070311221707400_bib94","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4161\/cc.2.4.433","article-title":"Multiple roles of the PI3K\/PKB (Akt) pathway in cell cycle progression","volume":"2","author":"Liang","year":"2003","journal-title":"Cell Cycle"},{"issue":"4","key":"2025070311221707400_bib95","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2443.2007.01071.x","article-title":"The PI3K-Akt pathway promotes microtubule stabilization in migrating fibroblasts","volume":"12","author":"Onishi","year":"2007","journal-title":"Genes Cells"},{"issue":"7","key":"2025070311221707400_bib96","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3324\/haematol.2012.066175","article-title":"The PI3K\/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma","volume":"98","author":"Chatterjee","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"2025070311221707400_bib97","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/ijc.32383","article-title":"HSP70\/HSF1 axis, regulated via a PI3K\/AKT pathway, is a druggable target in chronic lymphocytic leukemia","volume":"145","author":"Frezzato","year":"2019","journal-title":"Int J Cancer"},{"issue":"8","key":"2025070311221707400_bib98","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1074\/jbc.M110.172882","article-title":"PI3K-mTORC1 attenuates stress response by inhibiting cap-independent Hsp70 translation","volume":"286","author":"Sun","year":"2011","journal-title":"J Biol Chem"},{"issue":"10","key":"2025070311221707400_bib99","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/s43018-024-00814-0","article-title":"BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models","volume":"5","author":"Rauh","year":"2024","journal-title":"Nat Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024025102\/2383788\/blood_bld-2024-025102-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024025102\/2383788\/blood_bld-2024-025102-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T15:22:34Z","timestamp":1751556154000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/1\/89\/536006\/Large-scale-dependency-and-drug-screens-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025102","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,3]]},"published":{"date-parts":[[2025,7,3]]}}}